[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631479":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":56,"collaborators":26,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":26,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":26,"enrollmentInfo":69,"targetDuration":26,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":80,"whyStopped":26,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Chengdu Jinjiang Maternity and Child Health Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intranasal Dexmedetomidine Group","EXPERIMENTAL","Participants in this arm will receive a single dose of intranasal dexmedetomidine 50 μg (one spray of 25 μg per nostril, total two sprays) immediately before initiation of Combined Spinal-Epidural labor analgesia. Labor analgesia follows standard protocol using ropivacaine and sufentanil via patient-controlled epidural analgesia pump.",[13],"Drug: Dexmedetomidine",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo (Normal Saline) Group","PLACEBO_COMPARATOR","Participants in this arm will receive a single dose of intranasal normal saline (one spray per nostril, total two sprays) immediately before initiation of Combined Spinal-Epidural labor analgesia. Labor analgesia follows standard protocol using ropivacaine and sufentanil via patient-controlled epidural analgesia pump.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Dexmedetomidine","A single intranasal dose of dexmedetomidine 50 μg (25 μg per nostril) administered before combined spinal-epidural labor analgesia. Labor analgesia is maintained with ropivacaine and sufentanil via patient-controlled epidural analgesia pump.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Intranasal normal saline (one spray per nostril, total two sprays) administered as a single dose before initiation of Combined Spinal-Epidural labor analgesia. Identical in appearance, color, odor, and packaging to the dexmedetomidine nasal spray to maintain blinding.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Bo Liu","CONTACT","+8618502846036","liubojjfy@163.com",[38],{"facility":39,"status":26,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Chengdu Jinjiang District Women & Children Health Hospital","Chengdu","Sichuan","610011","China","CN",{"type":46,"coordinates":47},"Point",[48,49],104.06667,30.66667,{"lat":49,"lon":48},[52],{"name":53,"role":34,"phone":54,"phoneExt":26,"email":55},"jianjun mao","+8615008460156","jiafeijjfy@163.com",{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Fei Jia","Director of Anesthesiology Department","100631479","intranasal-dexmedetomidine-for-prevention-of-intrapartum-fever-100631479",false,"NCT07501221","Intranasal Dexmedetomidine for Prevention of Intrapartum Fever","Intranasal Dexmedetomidine and Labor Analgesia-Related Intrapartum Fever: A Randomized Controlled Trial","Inclusion Criteria:\n\n* ASA physical status II or III\n* Age ≥ 18 years\n* Singleton pregnancy, cephalic presentation\n* No contraindications to neuraxial anesthesia and voluntarily requesting labor analgesia\n\nExclusion Criteria:\n\n* Maternal temperature ≥ 37.3°C before labor analgesia\n* Allergy to α2-adrenergic receptor agonists\n* Severe pregnancy complications or systemic diseases\n* Use of analgesics, nonsteroidal anti-inflammatory drugs, or other medications that may affect body temperature within one week prior to enrollment\n* Heart rate \\\u003C 60 bpm or systolic blood pressure \\\u003C 90 mmHg before labor analgesia\n* Severe rhinitis or nasal deformity\n* Premature rupture of membranes","FEMALE","18 Years",{"count":70,"type":71},446,"ESTIMATED","INTERVENTIONAL",[74],"NA","Brief Title: Intranasal Dexmedetomidine for Prevention of Intrapartum Fever This study aims to evaluate the effect of intranasal dexmedetomidine (Dex) administered before neuraxial labor analgesia on the incidence of intrapartum fever in women undergoing vaginal delivery.\n\nThis prospective, randomized, double-blind, placebo-controlled trial will enroll 446 parturients scheduled for vaginal delivery with neuraxial labor analgesia at Chengdu Jinjiang Maternal and Child Health Hospital from 2026 to 2027. Participants will be randomly assigned in a 1:1 ratio to receive either intranasal Dex (50 μg) or an equal volume of normal saline before the initiation of labor analgesia.\n\nPrimary Outcome Measure:\n\nIncidence of intrapartum fever (temperature ≥ 38.0℃) from initiation of labor analgesia to 2 hours postpartum\n\nSecondary Outcome Measures:\n\nTemperature-related outcomes: Incidence of fever at thresholds of ≥ 37.5℃ and ≥ 38.5℃; hourly temperature trends assessed by continuous wireless axillary monitoring Analgesic effect: NRS pain scores before labor analgesia and at 30 minutes, 1 hour, and 3 hours after analgesia Sedative effect: Ramsay Sedation Scale scores at the same time points Maternal safety: Incidence of bradycardia (heart rate \\\u003C 60 bpm), hypotension (systolic blood pressure \\\u003C 90 mmHg or \\\u003C 20% of baseline), nausea, vomiting, oversedation (Ramsay ≥ 4), and respiratory depression (SpO₂ \\\u003C 90%) Labor characteristics: Duration of first, second, and third stages of labor, total labor duration, and duration of labor analgesia Delivery outcomes: Mode of delivery (spontaneous vaginal delivery or cesarean section) and total consumption of local anesthetics Neonatal outcomes: Apgar scores at 1, 5, and 10 minutes, and NICU admission rate We hypothesize that intranasal Dex administered before labor analgesia will significantly reduce the incidence of intrapartum fever compared to placebo. This study is expected to provide a novel, non-invasive, and effective strategy for preventing epidural-related maternal fever, thereby improving maternal safety and perinatal outcomes in women undergoing vaginal delivery.",[77],"Intrapartum Fever",[79,77,23],"labor analgesia","NOT_YET_RECRUITING","2026-03-26",{"date":83,"type":84},"2026-03-30","ACTUAL",{"date":86,"type":71},"2026-05-01",{"date":88,"type":71},"2027-10-01",{"name":5,"class":6},1]